martes, 17 de noviembre de 2026

Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial The unexpected result is good news for patients with acute myeloid leukemia

https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/ By Adam FeuersteinNov. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

No hay comentarios:

Publicar un comentario